Participants showed significant reductions in fatigue, improvements in feelings of liveliness, and enhanced cognitive performance measured by psychomotor vigilance testing
Over 72 weeks, participants on the highest dose of orforglipron who remained on treatment lost an average of 27.3 pounds about 12.4 percent of their body weight compared to just 2.2 pounds in the placebo group
Call 999 or go to your nearest A&E immediately if you experience any signs of a severe allergic reaction (anaphylaxis), including: Swelling of the face, lips, tongue, or throat Difficulty breathing or swallowing Dizziness, collapse, or a sudden drop in blood pressure A rapidly spreading rash with any of the above symptoms For urgent advice when you are unsure or cannot reach your trial coordinator, call NHS 111 (available 24 hours a day)
Theoretically, BPC-157 shows faster onset (4-6 days in animal models vs 2-6 weeks for human SSRIs), multi-system modulation rather than single-target effects, actual neuronal repair and regeneration (neuroprotection), no withdrawal syndrome in animals, and efficacy when given peripherally without extensive blood-brain barrier crossing
